Opioid-Induced Constipation - Epidemiology Insights to 2025

Publisher Name :
Date: 28-Jul-2017
No. of pages: 40
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Opioid-Induced Constipation -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Opioid-Induced Constipation in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Opioid-Induced Constipation. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Opioid-Induced Constipation. The report contains the targeted patient populations and the forecast methodology.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Key Coverage and Benefits

  • The Report includes the prevalent population and how will it change over the next eight years.

  • Coverage of key Opioid-Induced Constipation sub-populations and its prevalent or incident cases

  • Prevalent or incident cases segmented by age and sex.

  • The key differences in epidemiology patterns across the seven market segments.

Reasons to buy

  • Developing business strategies by understanding the trends shaping and driving the global Opioid-Induced Constipation market.

  • Identifying prevalent patient populations as well as risk factors in the global Opioid-Induced Constipation market will help to improve product design, pricing, and launch plans.

  • Organize sales and marketing efforts by identifying the best opportunities for Opioid-Induced Constipation therapeutics in each of the markets covered.

Opioid-Induced Constipation - Epidemiology Insights to 2025

Table of Contents

1. Report Introduction

2. Snapshot of Total Prevalent or Incident cases by 7 MM

3. Executive Summary
Key Findings

4. Opioid Induced Constipation Overview
Opioid Induced Constipation Definition
Pathophysiology
Symptoms
Etiology

5. Risk Factors Associated with Opioid Induced Constipation

6. Disease Burden & Unmet Need in the Market

7. Epidemiology and Patient Populations
Key Findings
Key Sources used and Forecast Methodology
Prevalent Cases and Incident Cases-2015-2025
Prevalent & Incident Cases by Category-2015-2025
Age-Specific Prevalent/ Incident Cases of Opioid Induced Constipation
Sex-Specific Prevalent/Incident Cases of Opioid Induced Constipation
Disease Type Specific Prevalent/Incident Cases of Opioid Induced Constipation

8.Prevalent & Incident Cases by 7 MM-2015-2025
Opioid Induced Constipation Epidemiology of United States-2025
Opioid Induced Constipation Epidemiology of United Kingdom-2025
Opioid Induced Constipation Epidemiology of Germany-2025
Opioid Induced Constipation Epidemiology of France-2025
Opioid Induced Constipation Epidemiology of Spain-2025
Opioid Induced Constipation Epidemiology of Italy-2025
Opioid Induced Constipation Epidemiology of Japan-2025

9. Key Takeaways

10. Appendix

11.Report Methodology

12. Consulting Services

13. Disclaimer

14. About Us

List of Tables

Table 1: Clinical subtypes of Indication
Table 2: Risk Factors
Table 3: Prevalence cases (%) Region wise
Table 4: Sources used for forecasting the data
Table 5: Opioid-Induced Constipation Global Epidemiology, (2015-2025)
Table 6: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), US (2015-2025)
Table 7: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), US (2015-2025)
Table 8: Prevalent Cases By Opioid-Induced Constipation Sub-population, US (2015-2025)
Table 9: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), United Kingdom (2015-2025)
Table 10: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), United Kingdom (2015-2025)
Table 11: Prevalent Cases By Opioid-Induced Constipation Sub-population, United Kingdom (2015-2025)
Table 12: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), Germany (2015-2025)
Table 13: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), Germany (2015-2025)
Table 14: Prevalent Cases By Opioid-Induced Constipation Sub-population, Germany (2015-2025)
Table 15: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), France (2015-2025)
Table 16: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), France (2015-2025)
Table 17: Prevalent Cases By Opioid-Induced Constipation Sub-population, France (2015-2025)
Table 18: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), Italy (2015-2025)
Table 19: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), Italy (2015-2025)
Table 20: Prevalent Cases By Opioid-Induced Constipation Sub-population, Italy (2015-2025)
Table 21: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), Spain (2015-2025)
Table 22: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), Spain (2015-2025)
Table 23: Prevalent Cases By Opioid-Induced Constipation Sub-population, Spain (2015-2025)
Table 24: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), Japan (2015-2025)
Table 25: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), Japan (2015-2025)
Table 26: Prevalent Cases By Opioid-Induced Constipation Sub-population, Japan (2015-2025)

List of Figures

Figure 1: Prevalence cases (%) Region wise
Figure 2: Sources used for forecasting the data
Figure 3: Opioid-Induced Constipation Global Epidemiology, (2015-2025)
Figure 4: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), US (2015-2025)
Figure 5: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), US (2015-2025)
Figure 6: Prevalent Cases By Opioid-Induced Constipation Sub-population,US (2015-2025)
Figure 7: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), United Kingdom (2015-2025)
Figure 8: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), United Kingdom (2015-2025)
Figure 9: Prevalent Cases By Opioid-Induced Constipation Sub-population,United Kingdom (2015-2025)
Figure 10: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), Germany (2015-2025)
Figure 11: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), Germany (2015-2025)
Figure 12: Prevalent Cases By Opioid-Induced Constipation Sub-population,Germany (2015-2025)
Figure 13: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), France (2015-2025)
Figure 14: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), France (2015-2025)
Figure 15: Prevalent Cases By Opioid-Induced Constipation Sub-population,France (2015-2025)
Figure 16: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), Italy (2015-2025)
Figure 17: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), Italy (2015-2025)
Figure 18: Prevalent Cases By Opioid-Induced Constipation Sub-population,Italy (2015-2025)
Figure 19: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), Spain (2015-2025)
Figure 20: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), Spain (2015-2025)
Figure 21: Prevalent Cases By Opioid-Induced Constipation Sub-population,Spain (2015-2025)
Figure 22: Prevalent Cases of Opioid-Induced Constipation (Ages =XX Years), Japan (2015-2025)
Figure 23: Prevalent Cases of Opioid-Induced Constipation By Sex (Males & Females), Japan (2015-2025)
Figure 24: Prevalent Cases By Opioid-Induced Constipation Sub-population,Japan (2015-2025)
  • United States Hypertrophic Cardiomyopathy Therapeutics Market Report 2017
    Published: 17-Aug-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Hypertrophic Cardiomyopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market ......
  • Raynauds Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 48
    Raynauds Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Raynauds Disease - Pipeline Review, H2 2017, provides an overview of the Raynauds Disease (Cardiovascular) pipeline landscape. Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smok......
  • Batten Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 53
    Batten Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H2 2017, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually......
  • Trigeminal Neuralgia - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 54
    Trigeminal Neuralgia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Pipeline Review, H2 2017, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape. Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain o......
  • Visceral Pain - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 55
    Visceral Pain - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H2 2017, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape. Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pai......
  • Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 119
    Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important c......
  • Liver Cirrhosis - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 90
    Liver Cirrhosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver wh......
  • Global Peptide Therapeutics Sales Market Report 2017
    Published: 14-Aug-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the global Peptide Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Peptide Therapeutics for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - ......
  • Global Hypertrophic Cardiomyopathy Therapeutics Market Research Report 2017
    Published: 14-Aug-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Hypertrophic Cardiomyopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Hypertrophic Cardiomyopathy Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North A......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs